CONTACTAbout UsCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Equal Entertainment LLC.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Bristol-Myers Squibb has begun enrolling patients in an early access program for the investigational HIV protease inhibitor atazanavir. The drug, currently in Phase III clinical trials, is a second-generation azapeptide protease inhibitor that in tests to date has been shown effective in lowering HIV viral loads without affecting blood lipid levels, which first-generation protease inhibitor medications often affect. The expanded access program is available to HIV-positive adults who are failing their current drug regimens and have HIV viral loads above 5,000 copies and T-cell counts below 300. The drug also will be made available to certain patients experiencing high blood triglyceride levels that can't be lowered by available medications. Patients can be enrolled in the expanded access program only by their physicians. Doctors may call (877) 726-7327 for more information about the program.
From our Sponsors
Most Popular
Latest Stories
Discover the diverse queer men of 'Elska Chisinau'
May 13 2025 4:53 PM
Police: Library book burner in Ohio escapes charges
May 13 2025 3:28 PM
Cooper Koch rocks Calvin Klein underwear in new campaign
May 13 2025 9:47 AM
Montana court strikes down ban on gender-affirming care for trans minors
May 13 2025 9:01 PM
Tennessee schools at risk after governor signs misgendering bill
May 13 2025 11:36 AM
LGBTQ+ people’s safety has plummeted across social media platforms: report
May 13 2025 9:00 AM
Judge said Naples Pride can be held in the sunshine for all ages
May 13 2025 5:19 PM
Exciting gay updates on 'The Office' spin-off 'The Paper'
May 13 2025 4:33 PM